<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Polymyxin B: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Polymyxin B: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Polymyxin B: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11886" href="/d/html/11886.html" rel="external">see "Polymyxin B: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12716" href="/d/html/12716.html" rel="external">see "Polymyxin B: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709216"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">When this drug is given IM, IV, or intrathecally, it should be given only to hospitalized patients, so as to provide constant supervision by a physician.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nephrotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Renal function should be carefully determined, and patients with renal damage and nitrogen retention should have reduced dosage. Patients with nephrotoxicity due to polymyxin B sulfate usually show albuminuria, cellular casts, and azotemia. Diminishing urine output and a rising blood urea nitrogen (BUN) are indications for discontinuing therapy with this drug.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neurotoxic reactions may be manifested by irritability, weakness, drowsiness, ataxia, perioral paresthesia, numbness of the extremities, and blurring of vision. These are usually associated with high serum levels found in patients with impaired renal function and/or nephrotoxicity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Concurrent therapy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The concurrent or sequential use of other neurotoxic or nephrotoxic drugs with polymyxin B sulfate, particularly bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, and colistin should be avoided.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuromuscular blockade:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The neurotoxicity of polymyxin B sulfate can result in respiratory paralysis from neuromuscular blockade, especially when the drug is given soon after anesthesia or muscle relaxants.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Use in pregnancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The safety of this drug in human pregnancy has not been established.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F211327"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F211308"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b> Dosing presented as units; 10,000 units = 1 mg.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="369ce704-426c-4757-9cb0-07521a3bf378">CNS infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS infection (adjunctive agent):</b>
<b>Intrathecal/Intraventricular:</b> 50,000 units once daily, in combination with systemic therapy (ESCMID/EUCAST [Tsuji 2019]; IDSA [Tunkel 2004]; IDSA [Tunkel 2017]; Segal-Maurer 1999). When intraventricular polymyxin B is administered via a ventricular drain, clamp drain for 15 to 60 minutes after administration (allows solution to equilibrate in CSF) (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]). <b>Note: </b>Use a preservative-free preparation. Intraventricular administration is generally reserved for use in patients who fail parenteral therapy despite removal of CSF shunt or when CSF shunt cannot be removed (Baddour 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea26c018-86d5-475b-b931-e8bd7f5f72b5">Ocular infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ocular infections:</b>
<b>Ophthalmic:</b> A concentration of 0.1% to 0.25% (10,000 to 25,000 units/mL) is administered as 1 to 3 drops every hour, then increasing the interval as response indicates. A subconjunctival injection of up to 100,000 units/day may be used for <i>P. aeruginosa</i> corneal and conjunctival infections. <b>Note:</b> Avoid total systemic and ophthalmic doses of &gt;25,000 units/kg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c5e8c9d0-5d7c-4644-9094-bf8954c6c36a">Pulmonary infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary infection (adjunctive agent) (off-label route):</b>
<b>Inhalation for nebulization:</b> 500,000 units every 12 hours; administer an aerosolized beta-2 agonist ~20 minutes prior to polymyxin B (Pereira 2007). <b>Note:</b> Use in combination with systemic antimicrobial therapy (ESCMID/EUCAST [Tsuji 2019]; IDSA/ATS [Kalil 2016]; Pereira 2007); some experts do not use inhaled polymyxin B (MacLaren 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d64f970-a7e6-463a-ac54-a631497c7616">Systemic infections, due to multidrug-resistant gram-negative bacilli</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic infections (eg, bacteremia, intraabdominal infections, meningitis, pneumonia [hospital-acquired or ventilator-associated], sepsis), due to </b>
<b>
<b>multidrug-resistant gram-negative bacilli (eg, </b>
<i>Pseudomonas aeruginosa,</i></b>
<i>
<b>Acinetobacter spp.)</b></i>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use actual body weight to calculate dose for patients with normal BMI (ESCMID/EUCAST [Tsuji 2019]; Kassamali 2015; Pai 2013; Sandri 2013a). To minimize development of resistance, use in combination with other antibiotics depending on infection site and susceptibilities (Bergen 2015; ESCMID/EUCAST [Tsuji 2019]; Kassamali 2015; Rigatto 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 20,000 to 25,000 units/kg loading dose, followed by a maintenance dose of 12,500 to 15,000 units/kg every 12 hours (ESCMID/EUCAST [Tsuji 2019]; Kassamali 2015; Sandri 2013a). Safety data for single infusions &gt;2,000,000 units are limited; pharmacokinetic data do not support capping at a maximum dose, but infusion-related adverse effects (eg, sudden thoracic pain, paresthesias, dizziness, dyspnea, hypoxemia) may increase with higher doses (ESCMID/EUCAST [Tsuji 2019]; John 2017; Sandri 2013a).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991006"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Manufacturer labeling recommends a dosage reduction in kidney impairment, and some additional studies suggest a relationship between kidney function and polymyxin B clearance (Avedissian 2018; Manchandani 2018; Yu 2021). However, the majority of clinical data suggest that total body clearance of polymyxin B is not altered substantially in kidney impairment (Kwa 2011; Sandri 2013a; Thamlikitkul 2016; Zavascki 2008). Decreasing daily doses in renal impairment may lead to suboptimal plasma exposure, adverse clinical outcomes, clinical failures, and resistance development (Elias 2010; ESCMID/EUCAST [Tsuji 2019]; Nelson 2015; Sandri 2013a; Zavascki 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV:</b> No dosage adjustment necessary for any degree of kidney dysfunction (ESCMID/EUCAST [Tsuji 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post-trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Bilbao-Meseguer 2018; Udy 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> There are no specific dosage adjustments recommended although there may be a need for higher doses; limited pharmacokinetic data are available (Avedissian 2018; Manchandani 2018; Yu 2021). Therapeutic drug monitoring has been recommended to guide polymyxin B dosing in patients with ARC (Avedissian 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b>
<b>IV:</b> Extent of dialyzability unknown: No dosage adjustment necessary (ESCMID/EUCAST [Tsuji 2019]). Because the extent of dialyzability is unknown, one of the twice daily doses should be administered after the dialysis on dialysis days (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>IV:</b> No dosage adjustment necessary (ESCMID/EUCAST [Tsuji 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b>
<b>IV:</b> No dosage adjustment necessary (ESCMID/EUCAST [Tsuji 2019]); Sandri 2013b).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): IV: </b>No dosage adjustment necessary (ESCMID/EUCAST [Tsuji 2019]). Because the extent of dialyzability is unknown, one of the twice daily doses should be administered after PIRRT treatment on PIRRT treatment days (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50988203"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doo drugH1Div" id="F49016066"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">Pharmacokinetic data do not support capping upper absolute doses in patients with high total body weight, however, data on the safety of infusions &gt;2,000,000 units remain limited (ESCMID/EUCAST [Tsuji 2019]; John 2017; Sandri 2013a). Infusion-related adverse effects may increase with higher doses (ESCMID/EUCAST [Tsuji 2019]; John 2017). Due to minimal data in morbidly obese patients, consider dosing based on adjusted body weight in these patients (Kassamali 2015; Pai 2013; Sandri 2013a).</p></div>
<div class="block doe drugH1Div" id="F211309"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F211321"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12716" href="/d/html/12716.html" rel="external">see "Polymyxin B: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Due to toxicity risks, the systemic use of polymyxin B should be limited to life-threatening, multidrug-resistant infection when less toxic alternatives are not effective or not tolerated. Multiple routes of administration available for use (eg, IV, IM, intrathecal, ophthalmic) and dosing differs based upon route; use extra caution in verification of dose and route of administration. Dosing presented in units; 10,000 units = 1 mg; use extra caution with prescribing and/or dispensing.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c226b1e-1aec-4b14-bc96-8e8d98867a6a">Severe, life-threatening, multidrug-resistant infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe, life-threatening, multidrug-resistant infection (excluding meningitis): Note:</b> From experience in adult patients, safety data for single doses &gt;30,000 units/kg/dose or total daily doses &gt;2,000,000 units<b>/day </b>are extremely limited (Kassamali 2015). Data in pediatrics are extremely limited; optimal dose unknown (Thomas 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Usual dose: 25,000 to 30,000 units/kg/<b>day</b> divided every 12 hours; reported range: 15,000 to 40,000 units/kg/<b>day </b>divided every 12 hours (Bradley 2019; Chiotos 2020; <i>Red Book</i> [AAP 2018], manufacturer's labeling). Based on adult recommendations, an initial loading dose of 25,000 units/kg has also been recommended (Chiotos 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">IM: 25,000 to 40,000 units/kg/<b>day</b> divided every 4 to 6 hours. <b>Note:</b> Routine IM administration not recommended due to severe pain at injection site.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Usual dose: 25,000 to 30,000 units/kg/<b>day</b> divided every 12 hours; reported range: 15,000 to 40,000 units/kg/<b>day</b> (Bradley 2019; Chiotos 2020; Hoeprich 1970; Siddiqui 2014; manufacturer's labeling). Manufacturer's labeling recommends a maximum dose of 25,000 units/kg/<b>day</b>; however, doses up to 40,000 units/kg/<b>day</b> have been reported in patients ≤12 years in a small case series (Siddiqui 2014). Based on adult recommendations, an initial loading dose of 25,000 units/kg has also been recommended (Chiotos 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">IM: 25,000 to 30,000 units/kg/<b>day</b> divided every 4 to 6 hours; <b>Note:</b> Routine IM administration not recommended due to severe pain at injection site.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="369ce704-426c-4757-9cb0-07521a3bf378">CNS infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS infection (including meningitis, ventriculitis, cerebrospinal fluid [CSF] shunt infections):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling:</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;2 years: Intrathecal: 20,000 units<b>/dose</b> once daily for 3 to 4 days <b>or</b> 25,000 units<b>/dose</b> once every other day; continue 25,000 units<b>/dose</b> once every other day for at least 2 weeks after cultures of the CSF are negative.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents: Intrathecal: 50,000 units<b>/dose</b> daily for 3 to 4 days, then every other day for at least 2 weeks after cultures of CSF are negative.</p>
<p style="text-indent:-2em;margin-left:4em;">Alternate recommendations: Limited data available: Children and Adolescents: Intraventricular or intrathecal: 20,000 to 50,000 units/day; due to the smaller CSF volume in infants, some guidelines recommend decreasing the infant dose; because adult dosage recommendations are based on ventricle size, smaller doses should be used in smaller patients (Hoeprich 1970; Landman 2008; IDSA [Tunkel 2004]; IDSA [Tunkel 2017]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea26c018-86d5-475b-b931-e8bd7f5f72b5">Ocular infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ocular infections:</b> Infants, Children, and Adolescents: Ophthalmic:</p>
<p style="text-indent:-2em;margin-left:4em;">Topical: 0.1% to 0.25% solution (prepared from parenteral injection): 1 to 3 drops every hour, then increasing the interval as response indicates.</p>
<p style="text-indent:-2em;margin-left:4em;">Subconjunctival injection: Up to 100,000 units/day not to exceed 25,000 units/<b>kg</b>/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Combined total therapy (systemic and ophthalmic instillation) should not exceed 25,000 units/kg/<b>day.</b></p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51153907"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal impairment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline: </i>Infants, Children, and Adolescents: The manufacturer's labeling recommends a dosage reduction; however, based on limited experience in adults, dosage adjustment may not be necessary (Chiotos 2020; ESCMID/EUCAST [Tsuji 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Renal toxicity during therapy:</i> If renal impairment (increased BUN or decreased urine output) occurs due to polymyxin B therapy, consider discontinuing therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b> Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling. No supplemental dose necessary (Cunha 1988).</p></div>
<div class="block dohp drugH1Div" id="F51153908"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling</p></div>
<div class="block adr drugH1Div" id="F211279"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Desquamation (Wen 2020), skin hyperpigmentation (Wen 2020), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, hypocalcemia (Goldin 2022), hypochloremia (O’Regan 1977), hypokalemia (Goldin 2022), hypomagnesemia (Goldin 2022), hyponatremia (O’Regan 1977)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Azotemia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local thrombophlebitis (IV injection site), pain at injection site (IM injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drug fever, meningism (with intrathecal administration), neurotoxicity (including asthenia, ataxia, blurred vision, dizziness, drowsiness, facial flushing, irritability, numbness of extremities, peripheral paresthesia [including oral paresthesia and stocking glove]) (Xing 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Ni 2020), state of neuromuscular blockade (including respiratory paralysis [Ning 2022]),</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Casts in urine, nephrotoxicity (Zavascki 2017), renal tubular disease (Goldin 2022)</p></div>
<div class="block coi drugH1Div" id="F211293"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to polymyxin B or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F211276"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Local reactions: May cause severe pain at IM injection site or thrombophlebitis at IV infusion site.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: <b>[US Boxed Warning]: May cause nephrotoxicity; avoid concurrent or sequential use of other nephrotoxic drugs.</b> Usual risk factors include preexisting renal impairment, advanced age and dehydration. Polymyxin B-induced nephrotoxicity may be manifested by albuminuria, cellular casts, and azotemia; monitor BUN, serum creatinine, and urinary analysis at baseline and as clinically indicated. Discontinue therapy with decreasing urinary output and increasing BUN. Data suggest polymyxin B undergoes a selective uptake process into renal cells, which plays a primary role in nephrotoxicity potential (Abdelraouf 2014). One small study in patients receiving polymyxin B with a normal baseline renal function observed an overall prevalence rate of nephrotoxicity of 46% with a median onset of 9 days (Dubrovaskaya 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity, which can also result in respiratory paralysis from neuromuscular blockade especially when the drug is given soon after anesthesia or muscle relaxants. Avoid concurrent or sequential use of other neurotoxic drugs.</b> Avoid concurrent use of curariform muscle relaxants and other neurotoxic drugs (eg, ether, tubocurarine, succinylcholine, gallamine, decamethonium, sodium citrate), which may cause respiratory depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Manufacturer labeling recommends a dosage reduction in kidney impairment, and some additional studies suggest a relationship between kidney function and polymyxin B clearance (Avedissian 2018; Manchandani 2018; Yu 2021). However, the majority of clinical data suggest that total body clearance of polymyxin B is not altered substantially in kidney impairment (Kwa 2011; Sandri 2013a; Thamlikitkul 2016; Zavascki 2008). Decreasing daily doses in renal impairment may lead to suboptimal plasma exposure, adverse clinical outcomes, clinical failures, and resistance development (Elias 2010; ESCMID/EUCAST [Tsuji 2019]; Nelson 2015; Sandri 2013a; Zavascki 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pregnancy: <b>[US Boxed Warning]: Safety in pregnant women not established.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• IM/Intrathecal/IV administration: <b>[US Boxed Warning]: Intramuscular/intrathecal/intravenous administration only to hospitalized patients.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Parenteral administration: Polymyxin B sulfate is most toxic when given parenterally; avoid parenteral use whenever possible.</p></div>
<div class="block foc drugH1Div" id="F211287"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500,000 units (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500,000 units (1 ea)</p></div>
<div class="block geq drugH1Div" id="F211272"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323703"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Polymyxin B Sulfate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500000 unit (per each): $6.54 - $17.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F211290"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 1 hour (ESCMID/EUCAST [Tsuji 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Inhalation for nebulization</b> (off-label use/route): Use with standard jet nebulizer connected to an air compressor; an aerosolized beta-2 agonist should be given ~20 minutes prior to polymyxin (Pereira 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrathecal/intraventricular:</b> May be administered intrathecally; intrathecal injections should only be administered in a hospital. Use a preservative-free preparation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ophthalmic:</b> May be administered as a subconjunctival injection or as topical ophthalmic drops.</p></div>
<div class="block admp drugH1Div" id="F52613619"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infuse over 60 to 90 minutes (Salvatore 2011; ESCMID/EUCAST [Tsuji 2019]) or by continuous infusion (per manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Not recommended for routine use in infants and children because of the severe pain associated with injection; should only be administered to hospitalized patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Intrathecal: May be administered intrathecally; only administer intrathecally to hospitalized patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: May be administered as a subconjunctival injection or as topical ophthalmic drops.</p></div>
<div class="block use drugH1Div" id="F211289"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pseudomonal infections:</b> Treatment of infections of the meninges and bloodstream caused by susceptible strains of <i>Pseudomonas aeruginosa.</i></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Serious infections:</b> Treatment of serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: <i>H. influenzae</i>, specifically meningeal infections; <i>Escherichia coli</i>; <i>Klebsiella aerogenes</i> (formerly <i>Enterobacter aerogenes</i>), specifically bacteremia; <i>Klebsiella pneumoniae</i>, specifically bacteremia.</p>
<p style="text-indent:-2em;margin-left:2em;">In meningeal infections, polymyxin B sulfate should be administered only by the intrathecal route.</p></div>
<div class="block mst drugH1Div" id="F5977966"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299903"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F211281"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Polymyxin B may enhance the nephrotoxic effect of Aminoglycosides. Polymyxin B may enhance the neurotoxic effect of Aminoglycosides. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacitracin (Systemic): Polymyxin B may enhance the nephrotoxic effect of Bacitracin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefaloridine [Cephaloridine]: Polymyxin B may enhance the nephrotoxic effect of Cefaloridine [Cephaloridine]. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefazedone: May enhance the nephrotoxic effect of Polymyxin B.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colistimethate: May enhance the nephrotoxic effect of Polymyxin B. Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate. Colistimethate may enhance the neurotoxic effect of Polymyxin B. Management: Coadministration of polymyxin B and other potentially neurotoxic or nephrotoxic agents, such as colistimethate, is generally not recommended. If this combination must be used, monitor carefully for enhanced neurotoxic and nephrotoxic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: Polymyxin B may enhance the adverse/toxic effect of Kanamycin.  Management: Coadministration of kanamycin and other potentially ototoxic or nephrotoxic agents, such as polymyxin B, is not recommended. If this combination must be used, monitor carefully neurotoxic, ototoxic, or nephrotoxic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Polymyxin B may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the nephrotoxic effect of Polymyxin B.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netilmicin (Ophthalmic): Polymyxin B may enhance the nephrotoxic effect of Netilmicin (Ophthalmic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.  Management: If possible, avoid concomitant use of neuromuscular-blocking agents and polymyxin B. If concomitant use cannot be avoided, monitor for deeper, prolonged neuromuscular-blocking effects (eg, respiratory paralysis) in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F211295"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]: Safety in pregnancy has not been established.</b></p>
<p style="text-indent:0em;margin-top:2em;">Limited data related to systemic use in pregnancy are available (Heinonen 1977; Kazy 2005). Based on the relative toxicity compared to other antibiotics, systemic use in pregnancy is not recommended (Knothe 1985). Due to poor tissue diffusion, topical use would be expected to have only minimal risk to the mother or fetus (Leachman 2006).</p></div>
<div class="block brc drugH1Div" id="F7306030"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if polymyxin B is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">If present in breast milk, polymyxin B is not absorbed well from a normal gastrointestinal tract.</p></div>
<div class="block mop drugH1Div" id="F211285"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Neurologic symptoms and signs of superinfection; renal function (decreasing urine output and increasing BUN may require discontinuance of therapy); polymyxin serum concentrations (to ensure adequate drug exposure particularly early in therapy) (ESCMID/EUCAST [Tsuji 2019]).</p></div>
<div class="block rer drugH1Div" id="F211288"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Target serum concentration is 2 mg/L for susceptible organisms (irrespective of reported MIC) (ESCMID/EUCAST [Tsuji 2019]). Serum concentrations &gt;5 mcg/mL are toxic in adults (Hoeprich 1970).</p></div>
<div class="block pha drugH1Div" id="F211275"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to phospholipids, alters permeability, and damages the bacterial cytoplasmic membrane permitting leakage of intracellular constituents</p></div>
<div class="block phk drugH1Div" id="F211292"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Not absorbed from GI tract.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Tissue diffusion is poor; critically ill patients: Central V<sub>d</sub>: ~0.09 L/kg; peripheral V<sub>d</sub>: 0.33 L/kg (Sandri 2013a); does not cross blood brain barrier into CSF or into the eye (Hoeprich 1970)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~60% (Kassamali 2015); 79% to 92% (critically ill patients) (Zavascki 2008)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 10.1 to 13.6 hours (Kwa 2008; Manchandani 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: Within 2 hours (Hoeprich 1970)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;1% as unchanged drug within first 12 hours; as therapy continues, up to 60% as unchanged drug in the urine [Evans 1999]); Critically ill adults: Urine (median: 4% [range: 0.98% to 17.4%] as unchanged drug) (Sandri 2013a)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539915"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Polimixina b richet</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">PMB | Polymax b</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Polymyxine pfizer</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bedfordpoly b | Polixil b | Polycid | Polytek b | Spox | Sulfato de Polimixina B</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ya le</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Polimixina b | Polimixina B | Polytek b</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Polymyxin b</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Poly mxb</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cbmyx | Gerpoly b | Myxinib | Paxyb | Poly b | Poly mxb | Polyfic | Polyhet | Polyiv | Polymyxin b | Polypure | Ultimus | Unipol b | Velimixin | Viacease b</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Polymyxin b abbott | Polymyxin b pfizer</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Poly mxb</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aerosporin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Polymyxine pfizer</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aerosporin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Retaxyl b</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Poly b | Poly mxb | Polymyxin b</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Polymyxin b | Polynat</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Polymyxin b</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Polymyxin b | Subvixin | Vellobaktin v | Vilimiksin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Polix | Polynat</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Poly mxb | Polymyxin b</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Poly mxb</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24733472">
<a name="24733472"></a>Abdelraouf K, Chang KT, Yin T, et al. Uptake of polymyxin B into renal cells. <i>Antimicrob Agents Chemother</i>. 2014;58(7):4200-4202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/24733472/pubmed" id="24733472" target="_blank">24733472</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29800496">
<a name="29800496"></a>Avedissian SN, Miglis C, Kubin CJ, et al. Polymyxin B pharmacokinetics in adult cystic fibrosis patients. <i>Pharmacotherapy</i>. 2018;38(7):730-738. doi:10.1002/phar.2129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/29800496/pubmed" id="29800496" target="_blank">29800496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33325056">
<a name="33325056"></a>Avedissian SN, Scheetz MH. Does renal function matter for polymyxin B? <i>Br J Clin Pharmacol</i>. 2021;87(7):2629-2632. doi:10.1111/bcp.14675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/33325056/pubmed" id="33325056" target="_blank">33325056</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Baddour L, Flynn PM, Fekete T. Infections of cerebrospinal fluid shunts and other devices. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25630411">
<a name="25630411"></a>Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. <i>Pharmacotherapy</i>. 2015;35(1):34-42. doi: 10.1002/phar.1537.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/25630411/pubmed" id="25630411" target="_blank">25630411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31872226">
<a name="31872226"></a>Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of carbapenem-resistant enterobacteriaceae infections in children. <i>J Pediatric Infect Dis Soc</i>. 2020;9(1):56-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/31872226/pubmed" id="31872226" target="_blank">31872226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3056882">
<a name="3056882"></a>Cunha BA, Friedman PE. Antibiotic dosing in patients with renal insufficiency or receiving dialysis. <i>Heart Lung</i>. 1988;17(6,pt 1):612-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/3056882/pubmed" id="3056882" target="_blank">3056882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25652747">
<a name="25652747"></a>Dubrovskaya Y, Prasad N, Lee Y, et al. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. <i>J Antimicrob Chemother</i>. 2015;70(6):1903-1907.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/25652747/pubmed" id="25652747" target="_blank">25652747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20685752">
<a name="20685752"></a>Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. <i>J Antimicrob Chemother</i>. 2010;65(10):2231-2237. doi:10.1093/jac/dkq285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/20685752/pubmed" id="20685752" target="_blank">20685752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10492501">
<a name="10492501"></a>Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. <i>Ann Pharmacother</i>. 1999;33(9):960-967.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/10492501/pubmed" id="10492501" target="_blank">10492501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17631984">
<a name="17631984"></a>Furtado GH, d'Azevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant <i>Pseudomonas aeruginosa</i>. <i>Int J Antimicrob Agents</i>. 2007;30(4):315-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/17631984/pubmed" id="17631984" target="_blank">17631984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33891671">
<a name="33891671"></a>Goldin LAM, Silva LN, Silva TFD, Delfino VDA. Polymyxin acute kidney injury: a case of severe tubulopathy. <i>J Bras Nefrol</i>. 2022;44(1):112-115. doi:10.1590/2175-8239-JBN-2019-0191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/33891671/pubmed" id="33891671" target="_blank">33891671</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Heinonen OP, Slone D, and Shapiro S, "Birth Defects and Drugs in Pregnancy," Publishing Sciences Group, Inc, Littleton, MA, 1977.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4319624">
<a name="4319624"></a>Hoeprich PD, “The Polymyxins,” <i>Med Clin North Am</i>, 1970, 54(5):1257-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/4319624/pubmed" id="4319624" target="_blank">4319624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6278236">
<a name="6278236"></a>Horton J and Pankey GA, “Polymyxin B, Colistin, and Sodium Colistimethate,” <i>Med Clin North Am</i>, 1982, 66(1):135-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/6278236/pubmed" id="6278236" target="_blank">6278236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29038262">
<a name="29038262"></a>John JF, Falci DR, Rigatto MH, Oliveira RD, Kremer TG, Zavascki AP. Severe infusion-related adverse events and renal failure in patients receiving high-dose intravenous polymyxin B. <i>Antimicrob Agents Chemother</i>. 2017;62(1). pii: e01617-17. doi: 10.1128/AAC.01617-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/29038262/pubmed" id="29038262" target="_blank">29038262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi: 10.1093/cid/ciw353.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25461655">
<a name="25461655"></a>Kassamali Z, Jain R, Danziger LH. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics. <i>Int J Infect Dis</i>. 2015;30:125-132. doi: 10.1016/j.ijid.2014.10.014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/25461655/pubmed" id="25461655" target="_blank">25461655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15907651">
<a name="15907651"></a>Kazy Z, Puhó E, and Czeizel AE, "Parenteral Polymyxin B Treatment During Pregnancy," <i>Reprod Toxicol</i>, 2005, 20(2):181-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/15907651/pubmed" id="15907651" target="_blank">15907651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2987132">
<a name="2987132"></a>Knothe H and Dette GA, "Antibiotics in Pregnancy: Toxicity and Teratogenicity," <i>Infection</i>, 1985, 13(2):49-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/2987132/pubmed" id="2987132" target="_blank">2987132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21507928">
<a name="21507928"></a>Kwa AL, Abdelraouf K, Low JG, Tam VH. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. <i>Clin Infect Dis</i>. 2011;52(10):1280-1281. doi: 10.1093/cid/cir137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/21507928/pubmed" id="21507928" target="_blank">21507928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17916420">
<a name="17916420"></a>Kwa AL, Lim TP, Low JG, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant gram-negative bacterial infections. <i>Diagn Microbiol Infect Dis</i>. 2008;60(2):163-167. doi:10.1016/j.diagmicrobio.2007.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/17916420/pubmed" id="17916420" target="_blank">17916420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18625681">
<a name="18625681"></a>Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. <i>Clin Microbiol Rev</i>. 2008;21(3):449-465.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/18625681/pubmed" id="18625681" target="_blank">18625681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA and Reed BR, "The Use of Dermatologic Drugs in Pregnancy and Lactation," <i>Dermatol Clin</i>, 2006, 24(2):167-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  MacLaren G, Spelman D. Polymixins: an overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29238962">
<a name="29238962"></a>Manchandani P, Thamlikitkul V, Dubrovskaya Y, et al. Population pharmacokinetics of polymyxin B. <i>Clin Pharmacol Ther</i>. 2018;104(3):534-538. doi:10.1002/cpt.981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/29238962/pubmed" id="29238962" target="_blank">29238962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25459221">
<a name="25459221"></a>Nation RL, Li J, Cars O, Couet W, Dudley MN, et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. <i>Lancet Infect Dis</i>. 2015;15(2):225-234. doi: 10.1016/S1473-3099(14)70850-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/25459221/pubmed" id="25459221" target="_blank">25459221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324272">
<a name="26324272"></a>Nelson BC, Eiras DP, Gomez-Simmonds A, Loo AS, Satlin MJ, et al. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. <i>Antimicrob Agents Chemother</i>. 2015;59(11):7000-7006. doi: 10.1128/AAC.00844-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/26324272/pubmed" id="26324272" target="_blank">26324272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33120846">
<a name="33120846"></a>Ni M, Meng X, Wang L, Zhao Y, Yu M, Shi S. Polymyxin B-induced rhabdomyolysis: a case report. <i>Medicine (Baltimore)</i>. 2020;99(43):e22924. doi:10.1097/MD.0000000000022924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/33120846/pubmed" id="33120846" target="_blank">33120846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36105193">
<a name="36105193"></a>Ning Y, Chu Y, Wu Y, Huang Y, Wang C, Jiang L. Case report: respiratory paralysis associated with polymyxin B therapy. <i>Front Pharmacol</i>. 2022;13:963140. doi:10.3389/fphar.2022.963140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/36105193/pubmed" id="36105193" target="_blank">36105193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-264790">
<a name="264790"></a>O'Regan S, Carson S, Chesney RW, Drummond KN. Electrolyte and acid-base disturbances in the management of leukemia. <i>Blood</i>. 1977;49(3):345-353.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/264790/pubmed" id="264790" target="_blank">264790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12878536">
<a name="12878536"></a>Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. <i>Antimicrob Agents Chemother</i>. 2003;47(8):2659-2562.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/12878536/pubmed" id="12878536" target="_blank">12878536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24051863">
<a name="24051863"></a>Pai MP. Polymyxin B dosing in obese and underweight adults. <i>Clin Infect Dis</i>. 2013;57(12):1785. doi: 10.1093/cid/cit604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/24051863/pubmed" id="24051863" target="_blank">24051863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17350201">
<a name="17350201"></a>Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. <i>Diagn Microbiol Infect Dis</i>. 2007;58(2):235-240. doi: 10.1016/j.diagmicrobio.2007.01.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/17350201/pubmed" id="17350201" target="_blank">17350201</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Polymyxin B for Injection, USP [prescribing information]. Lake Zurich, IL: Fresenius Kabi; February 2021.</div>
</li>
<li>
<div class="reference">
                  Polymyxin B for Injection [prescribing information]. Raleigh, NC: Xellia Pharmaceuticals USA, LLC; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26259799">
<a name="26259799"></a>Rigatto MH, Vieira FJ, Antochevis LC, Behle TF, Lopes NT, Zavascki AP. Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with <i>Acinetobacter baumannii</i> or <i>Pseudomonas aeruginosa</i> infections.<i> Antimicrob Agents Chemother</i>. 2015;59(10):6575-6580. doi: 10.1128/AAC.00494-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/26259799/pubmed" id="26259799" target="_blank">26259799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21751181">
<a name="21751181"></a>Roos D, Dijksman LM, Oudemans-van Straaten HM, et al, “Randomized Clinical Trial of Perioperative Selective Decontamination of the Digestive Tract versus Placebo in Elective Gastrointestinal Surgery,” <i>Brit J Surg</i>, 2011, 98(10):1365–72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/21751181/pubmed" id="21751181" target="_blank">21751181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21164382">
<a name="21164382"></a>Salvatore CM, Abdelraouf K, Hsing DD, Tam VH. Pharmacokinetics of polymyxin B in an infant with multidrug-resistant Klebsiella pneumoniae bacteremia. <i>Pediatr Infect Dis J</i>. 2011;30(6):537-539.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/21164382/pubmed" id="21164382" target="_blank">21164382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23697744">
<a name="23697744"></a>Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. <i>Clin Infect Dis</i>. 2013a;57(4):524-531. doi:10.1093/cid/cit334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/23697744/pubmed" id="23697744" target="_blank">23697744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23179561">
<a name="23179561"></a>Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG,et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. <i>J Antimicrob Chemother</i>. 2013b;68(3):674-677. doi: 10.1093/jac/dks437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/23179561/pubmed" id="23179561" target="_blank">23179561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10452648">
<a name="10452648"></a>Segal-Maurer S, Mariano N, Qavi A, Urban C, Rahal JJ Jr. Successful treatment of ceftazidime-resistant <i>Klebsiella pneumoniae</i> ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. <i>Clin Infect Dis</i>. 1999;28(5):1134-1138. doi: 10.1086/514754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/10452648/pubmed" id="10452648" target="_blank">10452648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25430979">
<a name="25430979"></a>Siddiqui NU, Qamar FN, Jurair H, Haque A. Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study. <i>BMC Infect Dis</i>. 2014;14:626.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/25430979/pubmed" id="25430979" target="_blank">25430979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15269195">
<a name="15269195"></a>Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. <i>J Antimicrob Chemother.</i> 2004;54(2):566-569.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/15269195/pubmed" id="15269195" target="_blank">15269195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864936">
<a name="34864936"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. <i>Clin Infect Dis</i>. 2022a;74(12):2089-2114. doi:10.1093/cid/ciab1013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/34864936/pubmed" id="34864936" target="_blank">34864936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35439291">
<a name="35439291"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). <i>Clin Infect Dis</i>. 2022b;75(2):187-212. doi:10.1093/cid/ciac268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/35439291/pubmed" id="35439291" target="_blank">35439291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27799209">
<a name="27799209"></a>Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, et al. Dosing and pharmacokinetics of polymyxin B in renal insufficiency. <i>Antimicrob Agents Chemother</i>. 2016. doi: 10.1128/AAC.01337-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/27799209/pubmed" id="27799209" target="_blank">27799209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30576264">
<a name="30576264"></a>Thomas R, Velaphi S, Ellis S, et al. The use of polymyxins to treat carbapenem resistant infections in neonates and children. <i>Expert Opin Pharmacother</i>. 2019;20(4):415-422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/30576264/pubmed" id="30576264" target="_blank">30576264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30710469">
<a name="30710469"></a>Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). <i>Pharmacotherapy</i>. 2019;39(1):10-39. doi:10.1002/phar.2209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/30710469/pubmed" id="30710469" target="_blank">30710469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284. doi: 10.1086/425368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33014066">
<a name="33014066"></a>Wen X, Luo C, Lyu W. Polymyxin B-induced skin hyperpigmentation. <i>Case Rep Med</i>. 2020;2020:6461329. doi:10.1155/2020/6461329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/33014066/pubmed" id="33014066" target="_blank">33014066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34386463">
<a name="34386463"></a>Xing H, Cheng C, Zhang Y, et al. Successful treatment with intrathecal and intravenous polymyxin B-based combination against MDR <i>Acinetobacter baumannii</i> meningitis in pediatric patient: a case report. <i>Front Pediatr</i>. 2021;9:564991. doi:10.3389/fped.2021.564991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/34386463/pubmed" id="34386463" target="_blank">34386463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33002196">
<a name="33002196"></a>Yu XB, Jiao Z, Zhang CH, et al. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions. <i>Br J Clin Pharmacol</i>. 2021;87(4):1869-1877. doi:10.1111/bcp.14576<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/33002196/pubmed" id="33002196" target="_blank">33002196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18840079">
<a name="18840079"></a>Zavascki AP, Goldani LZ, Cao G, et al, “Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients,” <i>Clin Infect Dis</i>, 2008, 47(10):1298-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/18840079/pubmed" id="18840079" target="_blank">18840079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17878146">
<a name="17878146"></a>Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. <i>J Antimicrob Chemother</i>. 2007;60(6):1206-1215.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/17878146/pubmed" id="17878146" target="_blank">17878146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993859">
<a name="27993859"></a>Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?. <i>Antimicrob Agents Chemother</i>. 2017;61(3):e02319-16. doi:10.1128/AAC.02319-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymyxin-b-drug-information/abstract-text/27993859/pubmed" id="27993859" target="_blank">27993859</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9790 Version 238.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
